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Introduction: Lung cancer is the leading cause of cancer-related 
deaths in the US. The reasons for higher incidence and poorer sur-
vival rates among black compared with white lung cancer patients 
have not been defined. We hypothesized that differential incidence 
of somatic cancer gene mutations may be a contributing factor. 
Previous genomic studies of non–small cell lung cancer (NSCLC) 
have not adequately represented black patients.
Methods: A matrix-assisted laser desorption/ionization and time-of-
flight mass spectrometry approach was used to analyze tumor DNA 
for 214 coding mutations in 26 cancer genes previously identified 
in NSCLC. The samples included NSCLC from 335 white patients 
and 137 black patients. For 299 of these, normal matched DNA was 
available and analyzed.
Results: Epidermal growth factor receptor (EGFR) exon 19 deletions 
were only detected in women cases, with increased odds for black women 
compared with white women (odds ratio = 3.914, 95% confidence inter-
val: 1.014–15.099, p = 0.048). Beyond race, variations in mutation fre-
quencies were seen by histology. DDR2 alterations, previously described 
as somatic mutations, were identified as constitutional variants.
Conclusions: This study is among the largest comparing somatic 
mutations in black and white patients. The results point to the molec-
ular diversity of NSCLC and raise new questions as to the impor-
tance of inherited alleles. Genomic tumor testing will benefit both 
populations, although the mutation spectrum appears to vary by sex, 
race, and histology.
Key Words: Non–small cell lung cancer, African American, muta-
tions, Oncogenes, Tumor suppressors.
(J Thorac Oncol. 2015;10: 250–255)
Lung cancers are a heterogeneous group of tumors tradition-ally categorized by histology, with the majority classified 
as non–small cell lung cancer (85%, NSCLC).1 NSCLC is 
further subdivided into adenocarcinomas (~45%), squamous 
cell carcinomas (~23%), and large cell carcinomas (~3%), 
with other subtypes representing the remaining approximately 
28%.1 Large-scale gene mutation profiling is transforming 
our knowledge of the heterogeneity of NSCLC.2 Genomic 
research now links specific oncogenes and recurring muta-
tions to the disease phenotype and provides a rationale for use 
of molecularly targeted treatments that are improving lung 
cancer patients’ outcomes.2
Black Americans are more likely to develop lung cancer 
and at an earlier age compared with white individuals despite 
lower rates of smoking in black adolescents.3–7 Moreover, 
blacks with lung cancer show worse outcomes, including 
shorter overall survival and increased mortality, which per-
sist when correcting for socioeconomic factors and unequal 
access to care.7 These data suggest diversity in disease etiol-
ogy across populations. The specifics of disease etiology gov-
ern the mutational processes giving rise to particular mutation 
patterns or signatures in cancer.8 Along these lines, study by 
Alexandrov et al.8 demonstrates that a specific mutation pro-
file in lung cancers is attributable to smoking. The same study 
also reports distinct mutation signatures in lung cancers not 
yet linked to a cause. It is predicted that more causally linked 
cancer mutation signatures will emerge when both the num-
bers of specimens and diversity of patients under investiga-
tion increases. Thus, we hypothesized that the frequencies of 
specific mutations in NSCLC will vary between black and 
white populations. Previous studies have compared muta-
tion frequencies according to race, but largely focused on 
a small subset of oncogenes—e.g., mutations in epidermal 
growth factor receptor (EGFR) and kirsten rat sarcoma viral 
oncogene homolog (KRAS)—and they yielded conflicting 
results.9–13 More comprehensive research is required to thor-
oughly investigate cancer gene mutation differences and to 
derive insight as to diagnostics and individualized treatment 
modalities that provide patient benefit. Here, we present find-
ings from a large-scale genomic study, with a large proportion 
of black patients, to examine whether the landscape of cancer 
relevant mutation frequencies varies according to race.
MATERIALS AND METHODS
Patients and Tissues
Biospecimen collection and outcomes data compila-
tion were done according to the Helsinki Declaration and 
approved by the Wayne State University School of Medicine 
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Institutional Review Board. Fresh-frozen or formalin-fixed 
paraffin-embedded specimens were collected from patients 
who underwent a surgical resection for diagnosed or suspected 
lung cancer. Frozen specimen procurement procedures were 
implemented to reduce the resection to freezing time inter-
val to less than 30 minutes. The overall procurement period 
ranged from 1985 to 2012 from five different case series. 
Frozen and archived FFPE specimens were reviewed to verify 
NSCLC diagnosis and to determine that tumor cell content 
was equal or greater than 70%. Only tumors pathologically 
confirmed to be NSCLC were included in the analysis. DNA 
from adjacent normal lung tissue was available and analyzed 
from 299 of the 472 cases. Demographic and clinical out-
comes data collected included: the dates of birth, diagnosis, 
and last follow-up or death; sex, race, tumor histology, patho-
logical, and clinical tumor stage (AJC staging manual, version 
6.0) and self-reported smoking history (defined as life-time 
never smoker for those who had smoked <100 cigarettes, for-
mer smoker for those who had quit cigarette smoking for more 
than 1 year, and smoker for all others).
Genetic Analysis
Frozen NSCLC and normal tissue specimens (~100 mg) 
were pulverized using sterilized and frozen mortar and pestles 
and DNA was isolated using resin or phenol-based extrac-
tion methods. DNA was isolated from paraffin-embedded tis-
sue using EZ1 Advanced magnetic bead technology, the EZ1 
DNA de-paraffinization method and the EZ1 DNA Tissue kit 
(Qiagen, Valencia, CA). All sample DNA quantity and qual-
ity was assessed using a Nanodrop spectrophotometer and 
Quantifiler assay (Life Technologies, Carlsbad, CA), a real-
time polymerase chain reaction-based approach for estimation 
of amplifiable DNA. A standard curve of known DNA con-
centrations was also analyzed for quantitation of each DNA 
sample.
Mutations were analyzed using the Sequenom 
MassARRAY System employing matrix-assisted laser desorp-
tion/ionization and time of flight mass spectrometry and the 
Sequenom LungCarta panel (Sequenom, San Diego, CA). 
The panel targets 214 sequence mutations in 26 oncogenes 
and tumor suppressors, which were previously identified in 
NSCLC.14,15 The genes include: AKT1, ALK, BRAF, DDR2, 
EGFR, EPHA3, EPHA5, ERBB2, FGFR4, JAK2, KRAS, 
MAP2K1, STK11, MET, NOTCH1, NRAS, NRF2, NTRK1, 
NTRK2, NTRK3, PIK3CA, PTCH1, PTEN, PTPN11, 
PTPRD, and TP53. The coding mutation types include syn-
onymous and nonsynonymous nonsense and missense point 
mutations, transversions and transitions, and short insertions 
and deletions(Supplementary Table 1, Supplementary Digital 
Content 1, http://links.lww.com/JTO/A748). The methodol-
ogy starts with polymerase chain reaction of small DNA seg-
ments (<100 base pairs) encompassing the DNA mutation 
sites in a multiplex reaction. A follow-up extension reaction 
adds a single base to extension primers, the nature of the base 
pair added to a primer affects its mass and time-of-flight; thus, 
a wild-type and mutation sequence can be differentiated and 
quantified. The sensitivity of the approach allows for detection 
of a mutation that represents ≥10% of the sample. The assay 
precision and accuracy for both FFPE and frozen specimen 
DNA were validated for as little as 60 ng by us and others16; 
however, typically 480 ng of sample DNA was analyzed for 
this study.
Statistical Analysis
Descriptive statistics were provided for patients’ demo-
graphic and clinical characteristics. Multivariable logistic 
regression was used to estimate the odds of having the genetic 
alteration, adjusted for potential confounders such as race 
(Black, reference: White), age (as continuous variable), sex 
(women, reference: men), tumor stage (II, III, or IV, reference: 
I), histology (squamous, other NSCLC, reference: adenocarci-
noma), and smoking status (never, unknown, reference: ever). 
All statistical tests were traditional two sided at a significance 
level of 0.05. Given the nature of this exploratory study, p val-
ues were not adjusted for multiple testing. Single nucleotide 
polymorphism (SNP) allele frequency within each subgroup 
of race was compared with the National Institutes of Health 
Heart, Lung and Blood Institute Grand Opportunity Exome 
Sequencing 6500 Project database17 using Fisher’s exact test. 
The statistical software R 3.0.0 (The R foundation for statis-
tical computing; http://www.r-project.org/foundation/) was 
used for all analyses.
RESULTS
Patient Characteristics
Descriptive statistics for the 472 NSCLC patients—137 
black individuals and 335 white individuals—who contributed 
specimens to this study are listed in Table 1. The proportions 
for histology, sex, stage, and smoking history are given strati-
fied by race; median age and pack years smoked by race are 
also indicated.
Frequency of Cancer Gene 
Mutations According to Race
An initial overview of the data from mass spectrometry 
analysis showed that for 180 of the 472 NSCLC specimens 
(38%) a mutation was detected (characteristics and muta-
tions identified for each specimen are provided in the online 
Supplementary Data file, Supplementary Digital Content 2, 
http://links.lww.com/JTO/A749). Comparing frequencies for 
individual mutations across race showed no significant differ-
ences for point mutations; however, there was a higher fre-
quency for the EGFR E746-T751>S deletion in exon 19 in 
tumor specimens from black patients compared with white 
patients (p = 0.076; Table 2). When the combined frequency 
of all variations of deletions detected at E746 (i.e., E746-T751 
and E746-T750) were considered, we observed that these 
mutations occurred exclusively in women and more often in 
black women than in white women (odds ratio [OR]: 3.914; 
95% confidence interval [CI]: 1.014–15.099; p = 0.048), after 
adjusting for age, stage, histology, race, and smoking status 
(Table 3). Across all mutation types, tumors from women were 
80% more likely to carry at least one mutation than those from 
men after adjustment for smoking, age, race, stage, and his-
tologic type (OR: 1.815; 95% CI: 1.200–2.747; p = 0.005) 
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(Supplementary Table 2, Supplementary Digital Content 1, 
http://links.lww.com/JTO/A748).
We also observed a race difference when we considered 
the numbers of specimens showing no mutation in black and 
white groups—68% versus 59%, respectively. Having adjusted 
for covariates including smoking, sex, stage, histology, and 
age, which are known determinates for the overall extent of 
genomic mutation in cancer specimens,18 the probability of 
having a mutation was decreased for the black patients (OR: 
0.582; 95% CI: 0.363–0.933; p = 0.025) (Supplementary 
Table 2, Supplementary Digital Content 1, http://links.lww.
com/JTO/A748). Figure 1 summarizes the number of single 
and multiple mutations observed in NSCLC specimens from 
black and white patients. Given the small numbers of mul-
tiple mutations, correlations cannot be tested for or meaning-
fully reported; however, mapping of co-occurring mutations 
displays a greater diversity of known mutations in tumors 
from white patients, which is consistent with overall sig-
nificantly more known mutations having been identified in 
NSCLC specimens from white patients.
Distinguishing Constitutional 
Polymorphisms from Somatic Mutations
In an overview of the data from mass spectrometry 
analysis, we identified that there were significant differences 
across race for genetic alterations in tumors that are also 
present in germline DNA, representing previously described 
single nucleotide polymorphisms in c-met (MET), notch 1 
(NOTCH1), and serine/threonine kinase 11 (STK11). The 
differentially detected SNPs included NOTCH p.V1671I and 
STK11 p.Y272Y (both increased in blacks; p < 0.0001), and 
MET p.N375S (increased in whites; p = 0.0117). Using the 
National Institutes of Health Heart, Lung and Blood Institute 
Grand Opportunity Exome Sequencing 6500 Project data-
base,17 we observed that all three SNPs demonstrated simi-
lar differences in comparing black and white frequencies in 
the general US population. However, NOTCH1 p.V1671I 
(p = 0.01), and MET p.N375S (p = 0.076) appear to be more 
frequent in the cancer patient population (Supplementary 
Table 3, Supplementary Digital Content 1, http://links.lww.
com/JTO/A748). All of these SNPs are in the National Center 
for Biotechnology Information SNP database although they 
have previously been highlighted as mutations in the literature 
or COSMIC database.15,19–22
We proceeded to analyze matched normal lung DNA from 
299 cases to confirm these SNPs and to identify other variants 
that might be inherited. Our efforts identified seven constitutional 
polymorphisms in the dataset, described in Table 4. Included 
among them was EGFR p.R776H, an activating mutation only 
recently identified as inherited in a single case study of a non-
smoking mother–daughter pair diagnosed with lung cancer.20 In 
this study, we identified it in normal and corresponding malignant 
tissue from a single white patient in our cohort of 472 patients 
(0.2%). Also of note, two DDR2 SNPs were detected in matched 
normal and tumor specimens: DDR2 p.L63V in a white patient 
TABLE 1.  Patient Characteristics
Variables
Race
Black
(n = 137)
White
(n = 335)
Age
  Median 60.8 66.1
  Range(min, max) (29.3, 84.7) (25.8, 83.7)
Gender
  Women 80 (58%) 116 (35%)
  Men 57 (42%) 219 (65%)
Histology
  Adenocarcinoma 92 (67%) 162 (48%)
  Squamous cell 29 (21%) 133 (40%)
  NSCLCa 16 (12%) 40 (12%)
Stage
  I 75 (55%) 219 (65%)
  II 17 (12%) 70 (21%)
  III or IV 45 (33%) 46 (14%)
Smoking history
  Ever 123 (90%) 273 (81%)
  Never 13 (9%) 22 (7%)
  Unknown 1 (1%) 40 (12%)
Pack years
  Median 38 50
  Range (min, max) (1, 130) (1, 300)
aNSCLC not sub-categorized in pathology review.
NSCLC, non–small cell lung cancer.
TABLE 2.  Frequency and Significance a for Specific Mutations 
Identified in Tumor Tissues among 472 Patients by Race
Gene Variant Black White p Value
EGFR delE746-T751>S 2% 0% 0.076
EGFR G719C 1% 0% 0.084
EGFR delE746-A750 4% 2% 0.116
TP53 R158L 1% 3% 0.189
aTop genes shown, ranked according to smallest p value of significance.
TABLE 3.  Logistic Regression for Odds Ratio of having EGFR 
Mutations delE746-T751>S or delE746-A750 Discovered Only 
in Women Samples
Variable Odds Ratio
Lower  
95% CI
Upper  
95% CI p Value
Race: Black 3.914 1.014 15.099 0.048
Age 1.056 0.993 1.123 0.081
Stage II 1.666 0.367 7.560 0.508
Stages III, IV 0.572 0.125 2.611 0.471
Histology NSCLC 0.000 0.000 Inf 0.991
Histology 
squamous
0.618 0.106 3.605 0.593
Smoke never 7.070 2.016 24.790 0.002
Smoke unknown 9.281 1.286 66.973 0.027
The model was built in the 196 women-only group. Reference groups: stage I, 
adenocarcinoma, or smoker.
CI, confidence interval; NSCLC, non–small cell lung cancer.
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and DDR2 p.G505S in a black patient. Both variants were previ-
ously characterized as activating mutations in NSCLC.15
Mutations Associated with Histologic Subtype
According to our data, mutation frequencies were lower in 
squamous cell carcinoma than in adenocarcinoma (OR: 0.583; 
95% CI: 0.374–0.909; p = 0.017). Further investigation of the 
frequency of somatic mutations in our 472 patient cohort accord-
ing to histology highlighted potential differences specifically for 
PIK3CA p.E545K (increased rate in squamous cell carcinoma, 
p = 0.029) and KRAS p.G12C/V (increased rate in adenocar-
cinoma, p < 0.001 and p = 0.016) (Supplementary Table 4, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A748). In general, adenocarcinomas exhibited greater numbers 
and higher diversity of mutations compared with squamous 
cell carcinomas (Fig. 2). It is noted that the level of diversity 
for co-occurring mutations discovered in squamous cell carci-
noma appears to resemble the relative level of diversity observed 
for black patients. Any observation of similarity is potentially 
misleading and not consistent with a histology bias in the study 
population, where to the contrary, squamous cell cancer is sig-
nificantly less represented in our black patient cohort compared 
with adenocarcinomas (21% versus 67%, p < 0.001).
DISCUSSION
Certain epidemiological data establishing disparities 
in NSCLC occurrence in black versus white patients are also 
suggestive of differences in disease etiology,3–7 and provide 
FIGURE 1.  Overall rates of detection and patterns of multimutations by race. The percentages of specimens where a single 
mutation or multiple mutations were discovered are presented in the pie graphs (left). The frequencies for the co-occurrence of 
mutated genes are displayed in the charts (right).
TABLE 4.  Description of Constitutional Polymorphisms and Frequencies in NSCLC Specimens
Gene Variant dbSNP# or Germline Reference
Cosmic# or Mutation 
Reference
Frequencya
p ValueBlack White
DDR2 (G505S) rs115169993 Hammerman 2011 (activating) 1 (1%; CI: 0%, 4%) 0 (0%; CI: 0%, 1%) 0.2903
DDR2 (L63V) rs144594252 Hammerman 2011 (activating) 0 (0%; CI: 0%, 3%) 1 (0%; CI: 0%, 2%) 1
EGFR (R776H) van Noesel 2013 COSM22940 0 (0%; CI: 0%, 3%) 1 (0%; CI: 0%, 2%) 1
MET (N375S) rs33917957 COSM28925; Krishnaswamy 
2009 (inhibitor resistant)
1 (1%; CI: 0%, 4%) 19 (6%; CI: 4%, 9%) 0.0117
NOTCH1 (V1671I) rs2229968 COSM33750 12 (9%; CI: 5%, 15%) 0 (0%; CI: 0%, 1%) <0.0001
STK11 (F354L) Launonen 2000 COSM1360 0 (0%; CI: 0%, 3%) 5 (1%; CI: 1%, 3%) 0.3278
STK11 (Y272Y) rs9282859 COSM29005 21 (15%; CI: 10%, 22%) 1 (0%; CI: 0%, 2%) <0.0001
aAmong 472 patients (137 African American, 335 European ancestry) with Wilson’s 95% CI.
dbSNP, data base single nucleotide polymorphism; CI, confidence interval.
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reasonable support for the notion that mutation profiles from 
the two populations will be different. Our study analyzed a 
broad variety of sequence mutations in NSCLC-linked genes 
and showed that the frequencies of coding mutations were 
within previously reported ranges for NSCLC (adenocarci-
noma and squamous cell combined: KRAS 11%, EGFR 8%, 
and PIK3CA 2%); and their frequencies were similar for 
black and white groups. The exception to this rule is the fre-
quency of small deletions in EGFR exon 19 at p.E746. Results 
showed the deletion was only detected in lung tumors from 
women, and with increased frequency in lung tumors from 
black women. The data suggest that women and black women 
more specifically may benefit from testing for this lesion, 
which is a predictive biomarker of response to anti-EGFR 
therapy. The clinical importance of a small deletion in EGFR 
exon 19 is further underscored by early evidence linking the 
aberration to longer progression-free survival relative to other 
EGFR mutations in metastatic cancer treated with first-line 
EGFR tyrosine kinase inhibitors.23
The types and or signatures of mutations that define can-
cer subtypes are attributable to causative mutational processes 
and evidence surrounding small deletions like p.E746-751 or 
p.E746-750 identified in EGFR exon 19 points specifically to 
defects in the DNA mismatch repair process.24 Furthermore, 
significant differences in the numbers of specimens for black 
patients showing no coding mutation, 68% versus 59% for 
whites, indicates that further genomic analyses should be done 
to more comprehensively characterize the range of mutation 
types occurring in NSCLC of black patients. For example, 
analysis of a larger gene set or copy number variation analysis 
may increase the percentage of tumors where an oncogene 
mutation is discovered. Whole genome sequencing of tumors 
from black patients may also identify novel genetic alterations 
in this population.
Our study is only the second to report a rare EGFR sin-
gle nucleotide germ line variant previously reported in a single 
case study to be oncogenic.20 Also, ours is the first report of the 
discovery of DDR2 variants in both normal and NSCLC tissue 
from individual patients. Specifically, the DDR2 p.G505S and 
DDR2 p.L63V variants are reported to be activating mutations 
in the cancer literature—mutations that supposedly render a 
cancer cell sensitive to the antigrowth effects of the targeted 
drug dasatinib.15 It cannot be determined from this study what 
bearing these inherited DDR2 variants may have had on can-
cer initiation and outcomes. Their discovery brings to mind 
ongoing efforts to understand to what degree inherited EGFR 
p.T790M mutations lead to an increased risk of developing 
lung cancer25–27; the same consideration must be given to 
DDR2 variants.
Finally, our analyses also honed in on histology-associ-
ated differences for individual mutation frequencies, adding 
to the growing body of evidence and emerging understand-
ing that histologic subtypes are distinguished by the mutations 
they harbor.2,28,29 It was observed that adenocarcinomas exhib-
ited greater numbers and greater diversity of mutations, and 
more often co-occurring mutations compared with squamous 
cell carcinomas (Fig. 2). It should not be interpreted that squa-
mous cell carcinoma is less apt to harbor driver mutations; 
on the contrary, the spectrum of cancer driver gene mutations 
associated with squamous cell histology is anticipated to be 
FIGURE 2.  Overall rates of detection and patterns of multimutations by histology. The percentages of specimens where a 
single mutation or multiple mutations were discovered are presented in the pie graphs (left). The frequencies for the co-occur-
rence of mutated genes are displayed in the charts (right).
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different. Thus, pointing to a need for future work to engage 
expanded genomic analyses to identify the full spectrum of 
cancer gene lesions in lung cancer subtypes. The same notions 
apply to our analyses across race, where fewer mutations were 
identified in black patient samples.
In summary, this study designed to test for differences 
in known somatic coding mutation frequencies across popula-
tions, presents a number of novel and unexpected findings. 
The important significant findings associated with race sup-
port the need for further study to molecularly define NSCLC 
in diverse patient populations. The particular discovery that 
DDR2 variants (DDR2 p.G505S and DDR2 p.L63V) classify 
as inherited alleles forces the need for further evaluation of 
their occurrence and oncogenic role in NSCLC.
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